Rani Therapeutics Holdings, Inc. Class A Share Price
RANIRani Therapeutics Holdings, Inc. Class A Stock Performance
Open $0.66 | Prev. Close $0.67 | Circuit Range N/A |
Day Range $0.65 - $0.70 | Year Range $0.40 - $3.85 | Volume 4,179 |
Average Traded $0.69 |
Rani Therapeutics Holdings, Inc. Class A Share Price Chart
About Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Rani Therapeutics Holdings, Inc. Class A Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
21-Jul-26 | $0.66 | $0.70 | +0.00% |
21-Jul-26 | $0.66 | $0.70 | +3.42% |
20-Jul-26 | $0.69 | $0.67 | -3.30% |
17-Jul-26 | $0.69 | $0.70 | +4.19% |
16-Jul-26 | $0.65 | $0.67 | -1.04% |
15-Jul-26 | $0.68 | $0.68 | +4.65% |
14-Jul-26 | $0.65 | $0.65 | +2.22% |